SignatureFD’s MaxCyte MXCT Stock Holding History

SignatureFD’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-161	Closed	-$502	–	3219
2023 Q3	$502	Sell	161 -40	-20%	-$161	﹤0.01%	3024
2023 Q2	$923	Buy	+201	New	+$924	﹤0.01%	2988
2022 Q4	–	Sell	-362	Closed	-$2K	–	3370
2022 Q3	$2K	Buy	+362	New	+$2.02K	﹤0.01%	2812

Other funds holding MXCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SignatureFD's MXCT Position: Q4 2023 in Review

SignatureFD sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 161 shares — an estimated $502 sold.

SignatureFD first reported a position in MXCT in Q3 2022 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

SignatureFD reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
SignatureFD sold 161 MaxCyte shares in Q4 2023, an estimated $502.
SignatureFD first reported a position in MaxCyte in Q3 2022 and held it in 3 quarters.
SignatureFD's MaxCyte position peaked at $2K in Q3 2022.
120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.